Results 311 to 320 of about 21,171,014 (388)
Some of the next articles are maybe not open access.
Haemophilia, 2021
Emicizumab has been shown to be safe and effective for prevention of bleeds in patients with severe haemophilia A (SHA), both with and without inhibitors.
J. Mason, G. Young
semanticscholar +1 more source
Emicizumab has been shown to be safe and effective for prevention of bleeds in patients with severe haemophilia A (SHA), both with and without inhibitors.
J. Mason, G. Young
semanticscholar +1 more source
Haemophilia, 2021
About 1%–5% of acquired haemophilia A cases affect mothers in the postpartum setting.
Natacha Dewarrat +7 more
semanticscholar +1 more source
About 1%–5% of acquired haemophilia A cases affect mothers in the postpartum setting.
Natacha Dewarrat +7 more
semanticscholar +1 more source
Haemophilia, 2020
Emicizumab is a recombinant humanized bispecific antibody that bridges factor IXa and factor X to mimic the cofactor function of factor VIII. It is approved to prevent bleeding in patients with haemophilia A (HA).
Isabella McCary +7 more
semanticscholar +1 more source
Emicizumab is a recombinant humanized bispecific antibody that bridges factor IXa and factor X to mimic the cofactor function of factor VIII. It is approved to prevent bleeding in patients with haemophilia A (HA).
Isabella McCary +7 more
semanticscholar +1 more source
The Lancet, 2003
The haemophilias are inherited disorders in which one of the coagulation factors is deficient. Although deficiencies of factor VIII (haemophilia A) and factor IX (haemophilia B) are well recognised, von Willebrand's disease is much more common. Rare defects can occur in any of the coagulation factors.
Paula H B, Bolton-Maggs, K John, Pasi
openaire +2 more sources
The haemophilias are inherited disorders in which one of the coagulation factors is deficient. Although deficiencies of factor VIII (haemophilia A) and factor IX (haemophilia B) are well recognised, von Willebrand's disease is much more common. Rare defects can occur in any of the coagulation factors.
Paula H B, Bolton-Maggs, K John, Pasi
openaire +2 more sources
Haemophilia, 1998
Summary. Gene therapy for haemophilia A would represent a significant improvement over the current treatment by providing prophylactic expression of FVIII and correction of the coagulation defect. Furthermore, a gene therapy protocol allowing simple, infrequent vector administration may extend haemophilia treatment to remote locations world‐wide that ...
C. A. Lee +6 more
openaire +2 more sources
Summary. Gene therapy for haemophilia A would represent a significant improvement over the current treatment by providing prophylactic expression of FVIII and correction of the coagulation defect. Furthermore, a gene therapy protocol allowing simple, infrequent vector administration may extend haemophilia treatment to remote locations world‐wide that ...
C. A. Lee +6 more
openaire +2 more sources
Doxycycline-induced acquired haemophilia A
BMJ Case Reports, 2021An 80-year-old man with no personal or family history of bleeding, presented to hospital with extensive haematomas and skin bruising after using doxycycline. His basic lab workup was concerning for a coagulopathy with an elevated activated partial thromboplastin time and significant anaemia.
Ejaz, Shah +3 more
openaire +2 more sources
Haemophilia A: molecular insights
Clinical Chemical Laboratory Medicine, 2007AbstractHaemophilia A is the most common inherited bleeding disorder caused by defects in theClin Chem Lab Med 2007;45:450–61.
CASTALDO, GIUSEPPE +8 more
openaire +4 more sources
Haemophilia, 2020
Haemophilia A (HA) is a rare X chromosome‐linked bleeding disorder resulting in missing or defective clotting factor VIII (FVIII) and causes large disease burden.
Xuewen Song +10 more
semanticscholar +1 more source
Haemophilia A (HA) is a rare X chromosome‐linked bleeding disorder resulting in missing or defective clotting factor VIII (FVIII) and causes large disease burden.
Xuewen Song +10 more
semanticscholar +1 more source
Pharmacotherapy of haemophilia A
Expert Opinion on Biological Therapy, 2011Haemophilia A is due to factor VIII (FVIII) deficiency. The main treatment is replacement therapy with FVIII concentrates. However, these concentrates carried a high risk of blood-borne viral infections and still have a high risk of inducing anti-FVIII inhibitors.An overview of products available and therapeutic options for haemophilia A management in ...
A. Gringeri +3 more
openaire +2 more sources
British Journal of Haematology, 1993
In the present study DNA from 281 unrelated haemophilia A patients including 15 inhibitor patients has been analysed by Southern blotting technique. Using various restriction enzymes, cloned factor VIII cDNA probes and genomic fragments we have identified 14 mutations. Six of the mutations are novel partial factor VIII gene deletions.
R, Schwaab +4 more
openaire +2 more sources
In the present study DNA from 281 unrelated haemophilia A patients including 15 inhibitor patients has been analysed by Southern blotting technique. Using various restriction enzymes, cloned factor VIII cDNA probes and genomic fragments we have identified 14 mutations. Six of the mutations are novel partial factor VIII gene deletions.
R, Schwaab +4 more
openaire +2 more sources